Raqualia Pharma (4579 JP): 1H FY12/24 flash update
Operating revenue increased to JPY1.4bn (+39.1% YoY), with an operating loss of JPY154mn and a recurring loss of JPY278mn. Royalty income from...
Investment Thesis and Valuation
Key Drivers Stable income of ¥ 0.5b - ¥1b from Animal Healthcare segment Pharma segment – royalty income from Tegoprazan (South K approved June...
No more insights